key: cord-0894997-pftyx1pr
authors: Myers, Catherine N.; Scott, J. Harwood; Criner, Gerard J.; Cordova, Francis C.; Mamary, A. James; Marchetti, Nathaniel; Shenoy, Kartik V.; Galli, Jonathan A.; Mulhall, Patrick D.; Brown, James C.; Shigemura, Norihisa; Sehgal, Sameep
title: COVID‐19 in Lung Transplant Recipients
date: 2020-06-10
journal: Transpl Infect Dis
DOI: 10.1111/tid.13364
sha: e2de4d22d6c80f455f43c9c5e9e73503bf1e7648
doc_id: 894997
cord_uid: pftyx1pr

Solid organ transplant recipients are considered at a high risk for severe COVID‐19 disease due to chronic immunosuppression, though their risk compared to that of the general population remains unclear. Management of lung transplant recipients can be particularly challenging given high levels of maintenance immunosuppression, high incidence of rejection, constant exposure of the graft to the external environment, and diagnostic uncertainty in patients with respiratory symptoms. There is currently limited data on manifestations, management, and outcomes in lung transplant recipients who develop this novel infection (1).

This article is protected by copyright. All 

This article is protected by copyright. All rights reserved (2 patients, 25%), and cystic fibrosis (1 patient, 12.5%). Five of eight patients (62.5%) were transplanted within the past year. Common comorbidities were diabetes mellitus (35.7%), hypertension (37.5%), hyperlipidemia (37.5%), chronic kidney disease (37.5%), and atrial fibrillation (37.5%). All patients were being maintained on the standard three drug immunosuppression regimen including a calcineurin-inhibitor, a nucleotide-blocking agent, and steroids at the time of diagnosis.

The most common presenting symptoms were dyspnea (75%), cough (75%), subjective fever (50%) and gastrointestinal symptoms (37.5 %); only two patients (25%) had a measured fever (> 38.0 C degrees) on the day of diagnosis. Two patients developed COVID pneumonia within 7 and 14 days respectively of their lung transplant. We believe these were healthcare acquired infections, since multiple providers were diagnosed around that time and donors were retrospectively tested negative. The remaining patients all presented to the emergency department and were admitted for further inpatient care. Three patients (37.5%) were admitted to our COVID-designated intensive care unit at diagnosis.

All patients underwent a chest CT scan. The predominant findings were bilateral ground glass opacities, present in all patients, and consolidation in five patients (62.5%) (Figure 1 ). In all single lung transplant recipients, both the native lung and allograft were involved. Lymphopenia (mean TLC 0.56 K/mm3) with associated elevation of inflammatory biomarkers such as CRP (mean 9.66 mg/dL), d-dimer (mean 1881ng/mL), and ferritin (mean 471 ng/mL) was noted in all eight patients. Three patients (37.5%) were noted to have superimposed bacterial infections. Patients were stratified into stages from mild to very severe disease (2); two patients (25%) had very severe disease, three patients (37.5 %) had severe disease, and three patients (37.5 %) had moderate disease. A summary of pertinent clinical and laboratory data is reported in Table 1 .

Without consensus guidelines to define treatment algorithms in this cohort, treatment decisions were made by a multidisciplinary COVID team and our transplant pulmonologists. All patients had

This article is protected by copyright. All rights reserved nucleotide blocking medications held, calcineurin-inhibitors were titrated to appropriate therapeutic levels, and steroid dosing was increased. Six patients (75%) received pulse-dose steroids (defined as at least 3 days of >/=125mg daily of methylprednisolone). All patients were started on empiric antibiotics selected based on individual risk factors. Two patients (25%) were enrolled in a blinded clinical trial assessing the utility of remdesivir in the treatment of COVID-19. Cytokine storm was treated with a combination of anakinra (IL-1 receptor antagonist) and IVIG in one patient (12.5 %), and tocilizumab (IL-6 receptor antagonist) in two patients (25 %).

Two patients (25 %) required mechanical ventilation, one of whom was proned. Two patients (25 %) required high-flow nasal cannula, one patient with regular nasal cannula (12.5%) and three patients (37.5%) were maintained without supplemental oxygen. With a mean follow up of 24 days, the mortality was 25%. Both patients who died were transplanted within two weeks prior to diagnosis; each had been successfully extubated post-transplant and subsequently required mechanical ventilation after COVID-19 diagnosis. One patient developed progressive sepsis and the other patient necrotizing pancreatitis, leading to death. Of the surviving patients, all six (75%) have been discharged with stable graft function.

Establishing a diagnosis of COVID-19 pneumonia can be particularly challenging in lung transplant recipients who present with respiratory symptoms. Similar to prior reports, gastrointestinal symptoms appear to be more common in transplant recipients. Fever does not appear to be a reliable sign and was observed in only 25% of our patients. In the appropriate clinical setting, chest CT findings of bilateral ground glass opacities and consolidation are important, especially given the high false negative rate of COVID-19 PCR. In our series, 37.5% of patients had a negative swab PCR, despite a clear clinical diagnosis. No trends in differences in outcomes or need for respiratory support were noted between PCR negative and positive patients. The involvement of the native lung in single lung transplant patients was helpful to differentiate COVID-19 from acute rejection.

This article is protected by copyright. All rights reserved

We observed a short-term mortality of 25% which is similar to previous reports in solid organ transplant recipients (3,4) . Induction therapy in the past year can leave patients unable to mount an adequate T-cell response, potentially making them vulnerable to infections. 62.5 % of our patients developed infection within a year from induction and both patients who died received basiliximab induction within the prior two weeks. However, it is encouraging that most patients (75%) continue to improve or have fully recovered, despite having moderate to severe disease requiring inpatient care. Additionally, recovered patients seem to have a preserved lung function. Long term impact of this novel infection on lung transplant recipients remains to be seen. 

COVID-19 in a lung transplant recipient

Mobilization and Preparation of a Large Urban Academic Center During the COVID-19 Pandemic

Covid-19 and Kidney Transplantation

Epub ahead of print